@Article{or.2023.042383,
AUTHOR = {QIUQIANG CHEN, XUEJUN GUO, WENXUE MA},
TITLE = {Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy},
JOURNAL = {Oncology Research},
VOLUME = {32},
YEAR = {2024},
NUMBER = {1},
PAGES = {49--60},
URL = {http://www.techscience.com/or/v32n1/54648},
ISSN = {1555-3906},
ABSTRACT = {Cancer immunotherapy has emerged as a promising strategy for the treatment of cancer, with the tumor
microenvironment (TME) playing a pivotal role in modulating the immune response. CD47, a cell surface protein,
has been identified as a crucial regulator of the TME and a potential therapeutic target for cancer therapy. However,
the precise functions and implications of CD47 in the TME during immunotherapy for cancer patients remain
incompletely understood. This comprehensive review aims to provide an overview of CD47’s multifaced role in TME
regulation and immune evasion, elucidating its impact on various types of immunotherapy outcomes, including
checkpoint inhibitors and CAR T-cell therapy. Notably, CD47-targeted therapies offer a promising avenue for
improving cancer treatment outcomes, especially when combined with other immunotherapeutic approaches. The
review also discusses current and potential CD47-targeted therapies being explored for cancer treatment and delves
into the associated challenges and opportunities inherent in targeting CD47. Despite the demonstrated effectiveness of
CD47-targeted therapies, there are potential problems, including unintended effects on healthy cells, hematological
toxicities, and the development if resistance. Consequently, further research efforts are warranted to fully understand
the underlying mechanisms of resistance and to optimize CD47-targeted therapies through innovative combination
approaches, ultimately improving cancer treatment outcomes. Overall, this comprehensive review highlights the
significance of CD47 as a promising target for cancer immunotherapy and provides valuable insight into the
challenges and opportunities in developing effective CD47-targeted therapies for cancer treatment.},
DOI = {10.32604/or.2023.042383}
}